Table 3.
ProTECT ranks on eight metachronous tumors across three MELANOMA patients.
| Sample and Source | Mel 21 | Mel 38 | Mel 218 | |||||
|---|---|---|---|---|---|---|---|---|
| LN | Skin (2012) | Skin (2013) | Abdominal Wall | Axilla LN | Breast | LN | ||
| RNA 1 | RNA 2 | |||||||
| Collection date | 1/30/2011 | 5/10/2012 | 6/6/2013 | 6/6/2013 | 4/16/2013 | 4/19/2012 | 2/14/2013 | 4/4/2005 |
| Total Variants | 1,532 | 2,140 | 1,681 | 1,679 | 1,213 | 1,121 | 1,259 | 2,176 |
| Actionable Variants | 332 | 400 | 393 | 391 | 219 | 216 | 224 | 449 |
| Total IARs | 105 | 137 | 114 | 116 | 73 | 80 | 86 | 155 |
| Vaccine Candidates with ProTECT ranks | NDC1:F169L (Reported as TMEM48 F169L) | SEC24A:P469L | EXOC8:Q656P | |||||
| 4 | 5 | 10 | 3 | 8 | 9 | 2 | 152 | |
| TKT:R438W | AKAP13:Q285K | PABPC1:R520Q | ||||||
| 6 | 6 | 4 | 4 | 14 | 80 | 17 | 140 | |
| CDKN2A:E153K | OR8B3:T190I | MRPS5:P59L | ||||||
| 21 | – | 18 | 17 | 11 | 13 | 14 | 26 | |
Highlighted ranks describe instances where pVAC-Seq and ProTECT both call a neoepitope. Green: Dominant epitope (existing immunity, neoantigen processed from endogenous protein), Orange: Subdominant epitope (immunity after vaccination, neoantigen processed from endogenous protein), Red: Cryptic epitope (immunity after vaccination, neoantigen not processed from endogenous protein).